Skip to content

News

Asarina Pharma AB today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB. The Company has entered into an...
Stockholm, 16 November 2023. Asarina Pharma AB (publ., “Asarina” or “the Company”) today provides an update on its partnering activities...
(Stockholm, 23 August 2023) Asarina Pharma today releases its First Half-Year Report for 2023. In addition to the financial statements for H1/2023, the...
Consultant Neurologist Dr. Heidi Biernat, Head of the Tourette Clinic at Copenhagen’s Bispebjerg University Hospital and Principal Investigator in...
The following resolutions were passed at the Annual General Meeting (the “AGM”) of Asarina Pharma AB (publ) (“the Company”) on...
The Phase IIa results demonstrated that Sepranolone could become the first-line pharma treatment for Tourette as it showed competitive tic reduction and...
The full Annual Report 2022 is available on: https://asarinapharma.com/investors/financial-reports/ Research and Development: This year, Asarina’s...
NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail. Right to participate...
THE STUDY: This was an open label, dual center, add-on study, randomizing 28 Tourette Syndrome patients, 20 males/8 females, 3 adolescents/25 adults between...
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS Recruitment completed: patient recruitment to Phase IIa study in Tourette completed in October 2022. A total of...